Descriptor English: | Cyclic Nucleotide Phosphodiesterases, Type 3 | ||||||
Descriptor Spanish: |
Fosfodiesterasas de Nucleótidos Cíclicos Tipo 3
| ||||||
Descriptor Portuguese: | Nucleotídeo Cíclico Fosfodiesterase do Tipo 3 | ||||||
Descriptor French: | Cyclic Nucleotide Phosphodiesterases, Type 3 | ||||||
Entry term(s): |
Cyclic Nucleotide Phosphodiesterase PDE3 Family Cyclic Nucleotide Phosphodiesterases, Type 3A Cyclic Nucleotide Phosphodiesterases, Type 3B Phosphodiesterase 3A Phosphodiesterase 3B Phosphodiesterase III Phosphodiesterase, cGMP-Inhibited cGMP Inhibited Cyclic Nucleotide Phosphodiesterase cGMP Inhibited Phosphodiesterase cGMP-Inhibited Cyclic Nucleotide Phosphodiesterase cGMP-Inhibited Phosphodiesterase |
||||||
Tree number(s): |
D08.811.277.352.640.150.300 D12.776.476.008.300 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D054684 | ||||||
Scope note: | A cyclic nucleotide phosphodiesterase subfamily that is inhibited by the binding of CYCLIC GMP to an allosteric domain found on the enzyme and through phosphorylation by regulatory kinases such as PROTEIN KINASE A and PROTEIN KINASE B. The two members of this family are referred to as type 3A, and type 3B, and are each product of a distinct gene. In addition multiple enzyme variants of each subtype can be produced due to multiple alternative mRNA splicing. |
||||||
Allowable Qualifiers: |
AD administration & dosage AE adverse effects AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis DE drug effects DF deficiency EC economics GE genetics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PH physiology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UL ultrastructure UR urine |
||||||
Entry Combination: |
antagonists & inhibitors:Phosphodiesterase 3 Inhibitors
|
||||||
Registry Number: | EC 3.1.4.17 | ||||||
Public MeSH Note: | 2008; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3 was indexed under 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE 1995-2007 |
||||||
History Note: | 2008(1995) |
||||||
DeCS ID: | 52678 | ||||||
Unique ID: | D054684 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 2008/01/01 | ||||||
Date of Entry: | 2007/07/09 | ||||||
Revision Date: | 2015/11/23 |
-
-
CHEMICALS AND DRUGS
Enzymes and Coenzymes [D08]Enzymes and Coenzymes -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins
|
Cyclic Nucleotide Phosphodiesterases, Type 3
- Preferred
Cyclic Nucleotide Phosphodiesterases, Type 3B
- Narrower
Cyclic Nucleotide Phosphodiesterases, Type 3A
- Narrower
Concept UI |
M0240466 |
Scope note | A cyclic nucleotide phosphodiesterase subfamily that is inhibited by the binding of CYCLIC GMP to an allosteric domain found on the enzyme and through phosphorylation by regulatory kinases such as PROTEIN KINASE A and PROTEIN KINASE B. The two members of this family are referred to as type 3A, and type 3B, and are each product of a distinct gene. In addition multiple enzyme variants of each subtype can be produced due to multiple alternative mRNA splicing. |
Preferred term | Cyclic Nucleotide Phosphodiesterases, Type 3 |
Entry term(s) |
Cyclic Nucleotide Phosphodiesterase PDE3 Family Phosphodiesterase III Phosphodiesterase, cGMP-Inhibited cGMP Inhibited Cyclic Nucleotide Phosphodiesterase cGMP Inhibited Phosphodiesterase cGMP-Inhibited Cyclic Nucleotide Phosphodiesterase cGMP-Inhibited Phosphodiesterase |
Concept UI |
M0354563 |
Preferred term | Cyclic Nucleotide Phosphodiesterases, Type 3B |
Entry term(s) |
Phosphodiesterase 3B |
Concept UI |
M0367999 |
Preferred term | Cyclic Nucleotide Phosphodiesterases, Type 3A |
Entry term(s) |
Phosphodiesterase 3A |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey